January 16, 2018Open Access

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

ESEric L. SimpsonOregon Health & Science University CFCarsten FlohrKing's College London LELawrence F. EichenfieldUniversity of California System

Key Points

Key points are not available for this paper at this time.

Abstract

When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Simpson et al. (Tue,) studied this question.

synapsesocial.com/papers/69dad66a4e9a02dbaa684ac6 https://doi.org/https://doi.org/10.1016/j.jaad.2018.01.017

AI에게 질문

Bookmark

View Full Paper